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Abstract
Background: Sharing interim data, results or result extrapolations is an important issue that can affect trial integrity.
The different ways in which Data Safety Monitoring Boards (DSMBs) share interim results with non-DSMB members and
the acceptability of such practices are poorly understood. Our objective was to undertake a narrative review specifically
on what kind of interim results, if any, should be shared by the DSMB with non-DSMB members and why.
Methods: We conducted a narrative review using a systematic search strategy of several databases and major health
research stakeholders. Literature was included if there was some discussion within the full text about sharing interim
trial results with non-DSMB members.
Results: About 79.6% (129/162) of included citations were based on author’s views, 16.7% (27/162) on research
guidelines and 3.7% (6/162) on surveys. The largest group of citations, 73/162 (45%), expresses the opinion or
argument against sharing interim results with exceptions. Trailing closely, 71/162 (43.8%) of the included citations
support the opinion or argument that interim results should not be shared and should remain confidential with the
DSMB. Half of the six surveys support sharing in some capacity, while the other three do not. Eleven circumstances
were found that potentially warrant interim result sharing by the DSMB; they relate to (1) usual practices by DSMBs, (2)
trial completion threatened, (3) patient safety, (4) regulatory approval and (5) other circumstances. Dominant risks for
sharing under these conditions are associated with introducing trial bias.
Discussion/conclusion: There was no majority view in the literature. However, the largest group of citations included
express the idea that interim results should remain confidential with the DSMB but also acknowledge circumstances
when they could be shared with non-DSMB members. Limitations of this review are that (1) the included literature
predominately provides personal perspectives, not evidence, and (2) surveys found globally focus on trial monitoring
practices lacking detailed information on what specifically to share, with whom and why. More research is needed with
the use of a detailed survey of the clinical trial community focused on DSMB sharing interim results, to better
understand and guide DSMB interim result sharing practices.
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Background
The Data Safety Monitoring Board (DSMB) or the Data
Monitoring Committee (DMC) is responsible for the
stewardship of a trial. This group can help oversee the
safety of patients in the trial by looking at unmasked
safety or efficacy data to make recommendations to the
Steering Committee (SC). They can also oversee, in
sequential designs, if the trial results have reached the
predefined amount of information needed to finish the
trial. Importantly, they also protect the trial from the bias
that could be introduced during the trial conduct [1, 2].
The case that triggered us to assess further this issue
of sharing interim trial information was described by
Anand et al. [3] when the funding sponsor asked the SC
and DSMB of a cardiovascular trial to provide them with
interim adaptive conditional power before approving the
request for additional funding requested by the investi-
gators. Adaptive conditional power “is the probability
that the trial will reach statistical significance if contin-
ued to completion if the difference specified in the trial
protocol is true, given the outcome events that have
already been observed, and the time remaining to observe
additional events among patients who are currently event
free” [3, 4]. It is a result extrapolation based on interim
relative efficacy results [2]. The DSMB refused to give this
information because they considered that sharing
adaptive conditional power would unmask the trial’s
interim results.
When we consider a review done by Grant et al. back
in 2005 [5] that globally looks at many issues related to
data monitoring and interim analysis, we see that there
seems to be an accord that interim results and DSMB
deliberations remain confidential. However, the review
are also mentions instances where interim results may
be shared with the independent unmasked statisticians
or other individuals such as the chair of the SC if the
DSMB deems it best to do so because of a safety issue.
See the Discussion section for a further discussion of
this review. Still, the review lacks certain details such as
the specifics of what kind of interim results are shared
and with whom. Sharing of interim trial data, results or
result extrapolations by the DSMB with individuals who
are non-DSMB members, who are responsible for the
conduct of the trial, can negatively affect trials [6]. One
of the major concerns related to sharing interim trial
results [1] is the potential for non-DSMB members to
consciously or subconsciously introduce bias that will
affect the final trial’s results [1, 7]. This is an especially
important issue for phase III trials, which are usually
designed and used to find definitive evidence on efficacy
and safety endpoints to inform practice or for regulatory
drug approvals [1, 2]. This case [2] and the review [5]
brought to mind the following questions: Is it possible
that there are other circumstances where the DSMB is
justified in sharing interim data, results or extrapolations
with non-DSMB members? If so, what information
would be shared in such circumstances and with whom?
The overall objective of this review and commentary is
to (1) provide a summative narrative review of the views
and opinions on the issue of the DSMBs sharing interim
results during the conduct of a clinical trial, particularly
phase III trials, with the Principal Investigators (PIs), the
sponsor, the SC, other parties responsible for the con-
duct of the trial or any other non-DSMB member(s);
and (2) discuss what interim data, results or result
extrapolations the DSMB should share, if anything at all,
with whom and under what circumstances. The infor-
mation required to inform this narrative review was
gathered from a systematic literature search. For simpli-
city, the remainder of this review will refer to any assort-
ment of interim data, interim results or interim result
extrapolations as interim results. Throughout the rest of
the review we will also refer to PIs, the sponsor, the SC,
investigators, site managers, independent unmasked stat-
isticians, the funder(s), or patients enrolled in the trial or
any other party responsible for the conduct or comple-
tion of the trial as non-DSMB members; we will be more
specific when needed.
Methods
A narrative review was considered the most appropriate
method to use because it allowed us to explore the
literature and inductively evaluate qualitative and quan-
titative information. We anticipated that most of the
literature we would find would be opinions, policies or
guidelines, and a narrative review would require an in-
ductive approach for theme analysis and categorisation.
To find literature discussing the issue of DSMBs sharing
interim results, a broad and comprehensive systematic
search of the literature was done in December 2015
within the databases of PubMed (includes all MEDLINE
citations), Web of Science, EMBASE and CINAHL from
the inception of all four databases using a detailed search
strategy for each of them, as outlined in Additional file 1.
Key phrases related to ‘Data Safety Monitoring Boards’
were utilised in each of the four databases as well as a
filter for articles in the English language.
The title and abstract for each citation that came up
within the search of each of the four databases were
reviewed. Citations were eligible and included for full-text
review if the title or abstract associated with a particular
citation met the following inclusion criteria: [(1) related to
DSMB issues OR (2) related to the management, oper-
ation, conduct, use, experience, or discussion of DSMBs]
AND (3) the article associated with the citation was pub-
lished in English. Subsequently, citations from the full-text
review were eligible and included for full-text information
extraction if there was some focused discussion or
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statement, within the full-text, about sharing interim trial
results with parties outside of the DSMB. Reference lists
from included articles were searched for other unique
articles discussing the issue of DSMBs sharing interim trial
results using the same inclusion criteria. Additionally, two
major textbooks that solely focused on the operation
and management of DSMBs were also reviewed and
consulted [1, 2]. These were found upon discussion
with a professor who is a health methodologist with
expertise in clinical trials.
We also searched regulatory, governmental and guideline
groups from the USA, Canada, UK, European Union and
Australia, and two international groups, the International
Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use (ICH)
[8] and the World Health Organisation (WHO) [9]. For a
list and details of the organisations that were searched
directly for relevant literature or information from their
respective websites, see Additional file 1. Two strategies
were used in combination to find relevant literature on the
issue of interim result sharing by the DSMB within major
governmental/regulatory/funding bodies and guideline
groups (Additional file 1). Documents and webpages on an
organisation’s website that had information about clinical
trial research and DSMBs, as indicated from a webpage’s or
document’s title or within the full text, were eligible and
included for full-text information extraction. A full-text
review was done immediately because most webpages or
documents found on these organisation websites are
not structured like most journal articles with an ab-
stract. Documents and pages from the full-text review
were eligible and included for full-text information
extraction if there was some focused discussion or
statement within the full text about sharing interim
trial results with parties outside of the DSMB. Please
note that within the Results and Discussion sections,
not all the citations included from our systematic
search of the literature for this review are cited in
this paper. A full citation list of articles found to support
this review in its entirety is given in Additional file 2. All
screening and full-text extraction was done independently
by one of the authors (VBD) for this narrative review and
then checked by co-reviewers (LM and LT). Information
extracted from the included full text pertained to the
sharing of interim trial results with parties outside of the
DSMB. Any disputes or concerns were resolved by con-
sulting co-reviewers (LM and LT). We worked inductively
and thus retrospectively with the included literature to
perform a categorisation and thematic literature analysis.
Analyst triangulation was used among co-reviewers (LM
and LT) with VBD to ensure that categorisation and the-
matic analysis of literature were sound. No changes were
made to the review process that was initially planned. Our
review is principled in pragmatism review because we
were not initially sure what categories or themes would
emerge from the literature. Please see the RAMESES
checklist [10] attached as Additional file 3.
Results
A total of 162 articles, documents, policies, guidelines
books or webpages were included for this review. See
Fig. 1 for a flow diagram showing the inclusion process
and the number of articles included.
There are mixed views and opinions on the issue of
the DSMBs sharing interim results during the conduct
of a clinical trial with non-DSMB members. Out of the
162 included articles, 129 (79.6%) were based on author’s
views, 27 (16.7%) on DSMB or trial research guidelines
and 6 (3.7%) on surveys of trialists. The literature falls
into three categories of opinions: Category 1 - literature
that expresses the opinion or argument against sharing
interim results, stating that they should remain confi-
dential with the DSMB (71/162, 43.8%); Category 2 - lit-
erature that expresses the opinion or argument against
sharing interim results with exceptions (73/162, 45.0%);
and Category 3 - literature that expresses the opinion or
argument in favour of sharing interim results by the
DSMB with a non-DSMB group (18/162, 16.8%). No one
group held the outright majority. However, the largest
two literature groups that were very close percentage
wise were Category 1 (43.8%) and Category 2 (45.0%).
Six surveys were also found out of the 162 included
articles that looked globally at trial monitoring practice
as described in detail in Table 1. These surveys did not
specifically focus on the issue of DSMBs sharing interim
results during the conduct of a clinical trial with non-
DSMB members. However, all of them asked at least one
question that was related to the issue and surveyed those
who were somehow involved in trials. Two of the six
surveys report results that are quantitatively unclear, as
their results are qualitatively described. The remaining
four of the six surveys report results quantitatively. The
target populations for these surveys varied, ranging from
directors of the statistical centres from 12 cancer co-
operative groups sponsored by the National Cancer
Institute (NCI) in the USA from 1993 [11], trialists of
past and ongoing trials [5, 12], PIs and biostatisticians
on DSMBs and Institutional Review Board (IRB) com-
munity representatives [13], major funders of trials,
regulatory agencies and other relevant organisations
related to trial research [5]. Methods to obtain the
sample also varied. Sampling frames included statistical
centres from 12 cancer cooperative groups sponsored by
the NCI in the US in 1993 [11], the US National Institutes
of Health (NIH) [12], ClinicalTrials.gov, a MEDLINE search
of articles pertaining to randomised controlled trials (RCTs)
from Biometrics or Statistics in Medicine, the Office of
Human Research Protection website [13], a database of
Borg Debono et al. Trials  (2017) 18:120 Page 3 of 13
Health Technology Assessment (HTA) programme and
Medical Research Council (MRC) trials [5] and a list of 25
handpicked organisations that are major funders of trials,
regulatory agencies and other relevant organisations related
to trial research [5]. Response rates ranged from 40%
to 100% [5, 11–13]. The number of responses to
these surveys varied from 12 to 309 [5, 11–13]. Re-
spondents were not chosen at random in two cases
[11, 12]. The other four surveys had some method to
select respondents at random [5, 13]. Survey collec-
tion methods included telephone interviews [5], email
surveys [5] and mail/paper surveys [5, 11–13].
Three of the six surveys [5, 11, 13] (one qualitatively
and two quantitatively reported) support the view
against sharing interim results, stating that they should
remain confidential with the DSMB (Category 1 view).
For one of the two surveys reported quantitatively [11],
all respondents (n = 9) indicated that NCI groups, at the
time the survey was administered, did not provide
unmasked outcome reports to the participants. For a
second question in the same survey asking about
which non-DSMB members had access to interim
data reports [11], it was reported that 70% of the re-
spondents (n = 10) indicated that non-DSMB members
do not access interim data reports. For the remaining
three respondents who answered this question, who
alternatively stated that non-DSMB members do have
access to interim data reports, there is no mention as
to who specifically gets this information and why. For
the second survey [13], as can be seen in Table 1, the
majority of respondents, all of whom were biostatisticians,
PIs or IRB community members, indicate that the sponsor
should be masked to interim data or results (percentages
can be viewed in Table 1). Masking of other non-DSMB
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Fig. 1 Flow diagram of the literature inclusion process
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members besides the sponsor was not mentioned. For the
minority of respondents who said “No” to this question
asking if the sponsor should be masked to interim data or
results (0% biostatisticians, 21.7% PIs and 37.0% IRB com-
munity members), there was no mention as to why this in-
formation should be shared with the sponsor. For the one
survey that qualitatively reported their results indicating
“Views on sharing the interim information with other
DMCs were consistent; the investigators were not en-
thusiastic about the DMC consulting others” [5],
there was no mention of whether there were respon-
dents with another view.
One survey [5] (quantitatively reported) supported the
Category 2 view: against sharing interim results but with
exceptions. The largest group of respondents from this
survey, for the question related to interim data or results
sharing (50%, 10/20), agreed with DSMBs sharing in-
terim results with non-DSMB members if it was neces-
sary, particularly for concerns related to participant
safety [5]. Specifically with whom this information would
be shared was not clear. For the remaining respondents to
this question, 30% (6/20) of respondents had no provision
for, or idea about, the DSMB sharing interim data or
results with non-DSMB members, and 20% (4/20) of
respondents disagreed with the DSMB interim data or
results sharing with non-DSMB members.
Two surveys [5, 12] (one qualitatively and one quanti-
tatively reported) supported the view in favour of shar-
ing interim results by the DSMB with a non-DSMB
group (Category 3 view). For the survey that was reported
quantitatively [5], all of the respondents to the question
related to interim data or results sharing (n = 17) indicated
that someone outside of the DSMB had access to interim
data or results during their trial. With whom interim re-
sults were shared was indicated as follows: 41% of respon-
dents indicated everyone except the participants, 35% of
respondents indicated key institute staff (one respondent
from this group said there was also provision for interim
data to be seen occasionally and confidentially by the
DSMB of another trial), 18% of respondents indicated only
the trial statistician and the DSMB and 6% stated that the
data centre personnel had access to interim data or
results. Why information was shared with these non-
DSMB members was not discussed. For the other survey
[12] that reported results qualitatively, it was indicated
that respondents (n = 12) from the US NIH support that
DSMB reports are to be confidential and privy only to
DSMB members. However, access is also granted to
selected US NIH staff, these being non-DSMB members.
Why information was shared with selected US NIH staff
was not discussed.
For the other 158 documents, which were not describ-
ing surveys, we assessed for a time trend to see where
the views and policies lie for the last ten years, back to
2006, in regard to the three categories we identified. For
the literature in Category 1, dating back to 1981, 54%
(37/68) of the literature comes from the past ten years
alone. For Category 2, the literature dates back to 1998.
About 24% (4/17) of the literature comes from the last
decade. For the literature in Category 3, dating back to
1991, 52% (38/73) of the literature comes from the past
ten years. The most recent literature, count and percent-
age wise, has predominately supported the DSMB not
sharing or not sharing but with some exceptions. We
also found that regulation, policy or guideline docu-
ments predominately support Category 3 (55%, i.e. 15/27
of the 27 regulation, policy or guideline documents
included in our review).
In regard to our second objective, there is a subset of
the literature within Category 2 or 3 literature that dis-
cusses what interim results the DSMB should share, with
whom and the circumstance (why). Eleven circum-
stances that may warrant the DSMB sharing interim re-
sults with non-DSMB members are explained in Table 2,
generally categorised under four themes: (1) current
usual practice by DSMBs, (2) trial completion is threat-
ened, (3) concern about patient safety and (4) regulatory
approval). There is also a category for other special cir-
cumstances that includes three unique situations for
DSMB sharing of interim results that did not fit into a
theme. Six of these eleven circumstances are supported
in the literature with real-life examples. What is shared
by the DSMB with non-DSMB members varies depend-
ing on the particular circumstance. For many of the
cases where sharing may be warranted, a risk or counter
argument to sharing is indicated where applicable. Most
of the risks with sharing in these circumstances are pre-
dominately associated with introducing bias in the trial
that will affect the final trial results. It is indicated in the
literature that there is always the potential that sharing
interim results with non-DSMB members may do harm
to a trial by disturbing equipoise [14, 15], as people may
make inaccurate impressions about what is happening
between treatment groups [3, 16–18]. It is explained that
when equipoise is disturbed with knowledge of interim
results by those operating and managing the trial and
those participating in the trial, there may be actions
people can take, either consciously or subconsciously [19],
that can bias the trial’s results [1, 16, 19]. The introduction
of bias can reduce the credibility and integrity [16, 20, 21]
of the trial, rendering the results questionable [16, 20, 22].
Discussion
What are the findings from the review?
We found three main views on the DSMB sharing in-
terim results with non-DSMB members. These views
were (1) against sharing (Category 1), (2) against sharing
interim results with exceptions (Category 2) and (3) in
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Table 2 Circumstances where interim result sharing may be warranted by the DSMB
Circumstance With whom would the
DSMB share?
What to share? Risk or counter argument Reference






needs to be evaluated
by the SC and sponsor
Specified representative(s)
of their trial’s SC and
sponsor




individuals privy to the
interim data should not
be a part of making
future trial decisions.






the DSMB has concerns
about the interim data
or results given to
them by the unblinded
independent statistician




Anything needed None made [16, 20, 27–38]
Theme 2) Trial completion
is threatened
Circumstance 3: When
the trial may have to
stop early because of
poor accrual due to
special circumstances,
and it may be possible
to improve accrual by
sharing interim data or
results, when all other
efforts to improve
accrual are exhausted
The public Some type of unmasked
interim result that will
encourage accrual
Risk: Risk of biasing trial
results even when special
conditions are met as
indicated by Stephens
et al. [39]. Sharing interim
results should be a
judgement call that
weights the benefits of
sharing against the





there is a need to
restore equipoise
when one of two
related trials finishes
first and threatens the
completion of the
unfinished trial
The public Sharing unmasked but
limited comparative




not need to share interim
information if it will
contribute important
information beyond what
was reported by a similar
trial that finished earlier.
This sentiment should be
expressed to all stakeholders









at interim in a trial
and there is another
similar trial still
underway
The DSMB of the similar trial Safety: Unmasked interim
safety result
Risk: Sharing may erode the
independence of each trial in
regards to the independent
confirmation of results
[1, 5, 6, 17, 23, 44–52]
[1]*
Circumstance 6: When
the DSMB assesses the
risk of there being a
serious adverse event
at interim for enrolled
patients in a particular
treatment group, but
Trial patients Safety: Unmasked interim
safety results
Risk: Unmasking of interim
safety results with the trial
patients may risk biasing
the trial results, but in
some cases it is ethically
imperative to let the
patients know of the severe
[1, 14, 18, 53, 54]
[1]*
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favour of sharing interim results (Category 3). The litera-
ture predominately supported Category 1 and Category
2 in similar proportions. We found that the literature in
Category 2 and Category 3 presented 11 cogent reasons
for sharing interim results by the DSMB with various
non-DSMB members in certain circumstances (Table 2).
The three surveys [5, 12] that support the Category 2
and Category 3 views do not specifically indicate what
should or should not be shared in circumstances that
may warrant sharing interim results. However, one of
the surveys [5] that support Category 2 indicates that
the DSMB having a safety concern is a circumstance that
justifies the DSMB sharing interim results with non-
DSMB members. In these 11 circumstances, what is
shared and with whom depends on the circumstance.
Six of the 11 circumstances (see Table 2) have real-life
Table 2 Circumstances where interim result sharing may be warranted by the DSMB (Continued)
continuing the trial may
still be desirable because
getting a definitive result
on a patient primary
endpoint is important
to the public and medical
community
safety risks to allow them
to decide whether they want
to continue in the trial and
before allowing the trial itself
to continue
Theme 4) Regulatory approval
Circumstance 7: When the
regulator is currently
assessing licensing
approval for a new drug/
treatment submitted with
results from a completed
trial and there is still a




The regulators Relevant unmasked interim
results that will help with
assessing the status that
should be given for a
licensing application
Risk: Interim review of the
second ongoing trial could
jeopardise its own integrity
and introduce bias, as the
public could prognosticate
the results of that trial based
on the regulator’s subsequent





Circumstance 8: When a
regulatory wants to
assess a drug for
conditional or accelerated/
expedited approval for
a manufacturer to be
able to market a
drug early
The regulators Unmasking interim results Risk: Bias could also be
introduced to the trial with
knowledge of regulatory
decisions made based on
interim results and known
threshold criteria for approval,
even if exact interim endpoints
are not shared publically





trials base interim trial
adaptive changes on
the trial’s interim results
Authorised qualified
persons at the sponsor
(1 or 2 people) who are
not participating in the
trial but can assist with
trial adaptations
Whatever is agreed upon
a priori
Risk: Unmasking of interim
data or results can introduce

















interim results that will
help with treatment
decision
Risk: Knowledge of an interim
endpoint result could influence
a clinical decision to have a
new treatment before safety of
that treatment is determined




or regulators are planning
for future studies, new
products or allocating





information. This could be:
• Control group event
rates OR
• Control group adverse
event rates OR
• Pooled event rate
Risk: Bias can be introduced to
the unfinished trial if new plans
are to be published and can be
interpreted by a wider audience.
Planning errors could result from
using uncertain interim results
[1, 6, 20, 71–74]
DAC Data Analysis Centre, DSMB Data Safety Monitoring Board, SC Steering Committee
Circumstances 3–8 have a real-life example and an asterisk (*) next to the associated reference(s) with the example
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examples (anecdotal evidence) where interim result shar-
ing by the DSMB with a non-DSMB member helped the
trial and the patients who were enrolled. However, for
most of these 11 circumstances, there are risks acknowl-
edged—mainly in regard to introducing bias that may
affect the trial’s final results. Based on these 11 circum-
stances that may occur, there is possible legitimacy in
the notion that what may or may not be shared and with
whom at interim should be a judgement call made by a
trial’s DSMB, where the DSMB as a group balances the
apparent risks and benefits in those circumstances that
arise regarding the need to protect both the safety of the
patients enrolled and the trial’s integrity. Sometimes the
DSMB may find that the benefits of sharing seem to out-
weigh the risks, as was illustrated by some real-life exam-
ples that supported 6 of the 11 circumstances. The DSMB
may also find that the risks of sharing are not worth the
benefits that could result. The opinion of the DSMB shar-
ing interim results is also supported in part by both Chal-
mers et al. [23] and Shah et al. [24]. Chalmers et al. [23]
comment on the need to share interim results when the
occasion is appropriate and to identify and plan for such
situations a priori when possible.
How do these findings compare with those of similar works?
While our review is unique in that it solely focuses on
the issues of interim result sharing by the DSMB with
non-DSMB members, another review, done earlier in
2005 by Grant et al. [5] under the auspices of the
National Health Service (NHS) in the UK, looks globally
at many issues related to data monitoring and interim
analysis. One of 23 questions they ask addresses in part
the issue with DSMB confidentiality of interim data.
They found within their literature review under Question
8: Should the DMC deliberations be open or closed
(confidential or secret as opposed to publicly available)?
that “There is near unanimity that the interim data and
the deliberations of the DMC should be absolutely confi-
dential” [5], which supports what we found in our review
with Category 1 literature which held a large percentage
of the literature reviewed (43.8%). However, a sub-
question to their Question 8 asked: Who outside the
committee should see the interim analysis and how is
this changed by whether the analyses were blinded or
unblinded? They indicate that some have suggested that
an independent unmasked statistician should see the
interim analysis [5], which is what we found for Circum-
stance 2 described in our Table 2. They also indicate that
the DSMBs may allow certain individuals such as the
chair of the SC to become unmasked to certain interim
results, especially if this is deemed by the DSMB of the
trial to serve patient/participant safety best [5]. For
Circumstances 5 and 6 in Table 2, we also find that a
severe safety issue in the trial is a potential driving factor
to share unmasked interim safety results with non-
DSMB members. Thus, their review [5] also supports
what we found in Category 2 literature: even though in-
terim results should remain confidential with the DSMB,
there are circumstances the DSMB must consider that
could warrant interim sharing outside of the DSMB.
Our review goes into detail about the circumstances that
may warrant sharing (see Table 2), and we do our best
to summarise all the views on this issue. Our intent was
also to discuss what to share and with whom in those
circumstances and, as described above, we found that it
greatly depends on the circumstance in which the DSMB
finds itself, in regard to the trial.
What are the key limitations?
One limiting factor of this review is that the majority of
the included literature was based on personal perspec-
tives (79.6%). Though these perspectives brought up im-
portant points, these views represent a small fraction of
all the professionals who are involved in trials and are
not based on evidence. Many of these views contributed
to describing the 11 circumstances found in Table 2,
where only 6 out of the 11 circumstances were sup-
ported by anecdotal evidence. The other 7 circumstances
were based on the author’s experience or view that
would warrant sharing by the DSMB if the DSMB
deemed it necessary and safe to do so.
Another limitation is that the six surveys do not fully
help us with our objective to understand, with empirical
evidence, what interim results, if any, the DSMB should
share, with whom and under what circumstances. They
globally focus on trial monitoring practices and not in
depth or specifically on the issue of DSMB sharing in-
terim results. At most, one or two questions within each
survey ask a question related to the DSMB sharing in-
terim results with other non-DSMB groups, but the
questions are not asked in a consistent way for all the
surveys. For instance, for three of these surveys, the
questions related to interim result sharing asks respon-
dents about their current practices regarding who has
access to unmasked outcome reports [5, 11, 12] at their
research institutions. For another survey, the question
very specifically asks respondents if the sponsor should
be masked to interim results [13]. For two of the surveys
[5], the question related to interim result sharing asks
respondents if they think unmasked interim results
should be shared with non-DSMB members. So,
although we can understand overall where support lies
from each survey in regard to sharing interim results,
and in some surveys we have a bit of information about
with whom interim results may be shared, it is still
extremely unclear what specific kind of interim result
should be shared, with whom that result should be
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shared and for what reason or circumstance. There is
not one survey that consistently asks the same group of
respondents who are trialists, what interim results
specifically should be shared, with a direct follow-up
question about who outside of the DSMB should share
that specific interim result and for what reason (why).
This is a complex topic. It is challenging for any survey
soliciting responses about global trial monitoring practices
to use one or two questions to sufficiently address and
provide enough information clarifying what interim results
the DSMB should share, if anything at all, with whom, and
why. Multiple questions or an entire survey dedicated to
the topic of DSMB interim result sharing is needed.
Implications of the findings
Our findings inform trialists and those who enact trial
policies and guidelines that there are mixed views on the
DSMB sharing interim results with non-DSMB mem-
bers. We could argue that out of the three categories,
the literature in Categories 1 and 2 dominates in that
the DSMB should not share interim results with non-
DSMB members, but the literature in Category 2 sug-
gests that there may exceptions. The exceptions include
11 possible circumstances as described in Table 2. How-
ever, the findings from this review need to be substanti-
ated with more research. The empirical evidence found
within three of the six surveys [5, 13] suggests there is
support for sharing interim results with certain non-
DSMB members, but the details on what specifically
should be shared and for what reason are unclear. Based
on the limitations described in the previous section,
more empirical evidence is needed to clarify specifically
what interim results should or should not be shared by
the DSMB with non-DSMB members, with whom and
for what reason or circumstance, to better inform moni-
toring practices, policies and guidelines that protect the
safety of the participants enrolled and trial validity.
For the situation described earlier by Anand et al. [3],
we also question: How useful is it to share unmasking
yet non-comparative interim results (e.g. control group
event rates without knowledge of the pooled events
rates)? Also, how useful is it to share results that appear
masking of comparative results (e.g. adaptive conditional
power or aggregate/pooled results by treatment group)?
It is thought that knowledge of aggregate/pooled results
can lead to concerns about making assumptions about
interim results [25, 26] that are not necessarily true,
which could lead to introducing bias in the trial. Know-
ledge of such potentially unmasking information, such
as the adaptive conditional power, could jeopardise the
integrity of the trial, as it does indicate the probability of
the trial showing a favourable significant result [2]. In
the case described by Anand et al. [3], the request for the
adaptive conditional power by the trial sponsor was
denied by the trial’s DSMB, and the decision to not
share was additionally supported by the trial’s SC, PI and
others outside of the trial who were consulted. There was
also mention of the DSMB sharing an ‘unconditional’
conditional power with the sponsor. This ‘unconditional’
conditional power calculation [3] was shared with the
sponsor because it is thought to mask the efficacy results
if given out at interim, but also provide reassurance to the
sponsor that the trial will have the power to answer the
primary hypothesis initially set out at the design stage of
the trial, when the trial is completed [3]. Is providing the
‘unconditional’ conditional power a helpful alternative to
sharing aggregate/pooled results? Should a result ex-
trapolation such as aggregate/pooled results or adaptive
conditional power be shared? How is such information
interpreted? The issue of sharing aggregate/pooled in-
terim results needs further investigation. More clarity is
also required on the specifics of sharing aggregate/
pooled interim results, particularly interim results that
are thought to be masking, such as the combined event
rate, and result extrapolations, such as adaptive condi-
tional power, that have been requested in the past [3].
Conclusions
Interim result sharing is an important issue because it af-
fects the validity of the results from confirmatory trials on
which we base regulatory and practise decisions, impact-
ing the health and lives of many. From this review, two
categories of the literature dominate (Category 1 and Cat-
egory 2), but not in majority as distinct groups. Category 1
is against sharing interim results, stating that they should
remain confidential with the DSMB, and Category 2
shares the same sentiment as Category 1 but additionally
acknowledges exceptions, that there are circumstances
that may warrant the DSMB to share interim results with
certain non-DSMB groups/members. What is shared with
these non-DSMB members depends on what the situation
calls for and should be assessed by the DSMB using their
expertise to balance risk(s) with the potential benefit(s)
regarding participant safety and trial validity and integrity.
Because of the limitations of the evidence found, collect-
ing more empirical evidence through a survey of the
general clinical trials community focused on the issue of
DSMB sharing interim results (what, if any, interim re-
sult(s) to share, with whom and under what circumstance)
is needed to better understand and guide DSMB interim
information sharing practices.
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